Business
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results
First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWI
About this update from Macrogenics, Inc.
[{"type":"image","alt":"MacroGenics, Inc.","displaySize":"","headline":null,"caption":"MacroGenics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/030baacf51876057e118509310b3ec94"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C1zbN.lNvnReOeBuDRQ_Bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/030baacf51876057e118509310b3ec94","width":300,"height":174}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers ","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 ","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 ","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ","length":87,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":454,"olType":false},{"type":"text","content":"ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2025.","length":395,"tagName":"p"},{"type":"text","content":"“In the first quarter, we advanced our innovative pipeline of clinical product candidates. Notably, we dosed the first patient in our Phase 2 LINNET study of lorigerlimab, which will evaluate patients with platinum-resistant ovarian cancer and clear cell gynecologic cancers. We believe lorigerlimab, a differentiated bispecific checkpoint inhibitor, may be uniquely positioned to address the significant unmet need in both indications,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “We are focused on continued clinical execution this year and look forward to sh...